Pork supply chain invests $6.5 million in novel vaccine platform
9 Aug 2022
Genvax Technologies, a startup dedicated to bringing advances in self-amplifying mRNA vaccine production to animal health, has secured $6.5 million in series seed funding. This funding moves the company toward USDA and international regulatory approval of its vaccines in anticipation of any foreign animal disease outbreak in order to increase health and profitability in livestock production.
The company's proprietary saRNA platform allows for rapid development of herd or flock-specific vaccines matched 100% to the variant strain circulating in an animal-production operation. By inserting a specific transgene or "gene of interest" matched to the variant strain into the platform, the saRNA can generate an antibody response without requiring the whole pathogen.